OrthoPediatrics (NASDAQ:KIDS - Free Report) had its price objective lowered by Truist Financial from $26.00 to $24.00 in a research report report published on Friday morning,Benzinga reports. The firm currently has a hold rating on the stock.
Other equities analysts also recently issued reports about the company. Lake Street Capital started coverage on OrthoPediatrics in a research report on Monday, April 7th. They issued a "buy" rating and a $37.00 target price for the company. Stifel Nicolaus reduced their target price on shares of OrthoPediatrics from $40.00 to $32.00 and set a "buy" rating on the stock in a report on Wednesday, March 5th. Finally, Needham & Company LLC restated a "buy" rating and issued a $42.00 price target on shares of OrthoPediatrics in a research note on Wednesday, April 9th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $37.00.
View Our Latest Analysis on KIDS
OrthoPediatrics Price Performance
NASDAQ KIDS traded down $0.01 during trading hours on Friday, hitting $20.97. 143,503 shares of the company's stock traded hands, compared to its average volume of 199,980. The company has a market capitalization of $509.30 million, a PE ratio of -17.05 and a beta of 1.17. The company has a debt-to-equity ratio of 0.19, a current ratio of 7.17 and a quick ratio of 3.68. OrthoPediatrics has a 52-week low of $20.37 and a 52-week high of $35.99. The firm's 50-day moving average is $24.07 and its 200-day moving average is $24.68.
OrthoPediatrics (NASDAQ:KIDS - Get Free Report) last issued its earnings results on Tuesday, March 4th. The company reported ($0.29) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.33) by $0.04. OrthoPediatrics had a negative return on equity of 5.78% and a negative net margin of 15.00%. The company had revenue of $52.67 million during the quarter, compared to analysts' expectations of $51.16 million. During the same period in the prior year, the business earned ($0.23) EPS. Equities analysts forecast that OrthoPediatrics will post -0.93 EPS for the current fiscal year.
Insider Buying and Selling
In other news, CEO David R. Bailey sold 6,620 shares of the firm's stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $24.86, for a total transaction of $164,573.20. Following the sale, the chief executive officer now owns 319,155 shares of the company's stock, valued at approximately $7,934,193.30. This trade represents a 2.03 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Gregory A. Odle sold 5,359 shares of the stock in a transaction that occurred on Tuesday, March 18th. The shares were sold at an average price of $24.86, for a total transaction of $133,224.74. Following the completion of the transaction, the insider now owns 148,788 shares in the company, valued at $3,698,869.68. This represents a 3.48 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 23,732 shares of company stock worth $589,978. Corporate insiders own 31.80% of the company's stock.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently bought and sold shares of the business. Quarry LP acquired a new position in shares of OrthoPediatrics during the 3rd quarter worth $25,000. R Squared Ltd purchased a new position in OrthoPediatrics in the fourth quarter valued at about $48,000. KLP Kapitalforvaltning AS acquired a new stake in shares of OrthoPediatrics during the 4th quarter valued at approximately $79,000. BNP Paribas Financial Markets boosted its stake in shares of OrthoPediatrics by 125.1% during the 3rd quarter. BNP Paribas Financial Markets now owns 3,471 shares of the company's stock worth $94,000 after acquiring an additional 1,929 shares in the last quarter. Finally, AlphaCentric Advisors LLC acquired a new stake in shares of OrthoPediatrics in the 4th quarter worth approximately $171,000. Institutional investors and hedge funds own 69.05% of the company's stock.
About OrthoPediatrics
(
Get Free Report)
OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products.
Further Reading
Before you consider OrthoPediatrics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and OrthoPediatrics wasn't on the list.
While OrthoPediatrics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
